B.Riley lowers Hyperfine stock price target on valuation adjustment

B.Riley lowered its price target on Hyperfine Inc. (HYPR) to $1.40 from $1.60, maintaining a Buy rating. Q3 2026 revenue was $6.0M, beating estimates, with a loss per share of $0.06. Revenue grew 73% YoY, and gross margin expanded to 57%. The company reaffirmed fiscal 2026 guidance and extended its cash runway into 2028.

Original reporting
Published Nov 18, 2026, 10:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 10:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$HYPR
Neutral
high confidence
Mentioned
$HYPR
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$HYPRNeutralMed
01

Why it matters

Earnings beat and cash strength may attract value‑oriented traders, while the target cut could trigger short‑covering.

02

Market read

Primary earnings disclosure for a micro‑cap; modest trading relevance.

03

What to watch

Potential future contracts or FDA approvals could further boost revenue beyond guidance.

Relevance 6/10Novelty 6/10Timing: post-market today

Background

Hyperfine is a micro‑cap medical imaging company reporting its Q3 FY2026 results and an analyst price‑target adjustment.

Company-level read

Ticker impact

$HYPRNeutralHigh confidence
Context

B.Riley lowered HYPR's price target to $1.40 and reported Q3 FY2026 results with revenue of $6.0M and a loss per share of $0.06.

Expected impact

likely modest upside as the market prices in the earnings beat and lower loss, tempered by the target reduction.

Evidence & confidence

The earnings beat and cash runway extension are positive, but the lower price target signals caution.

Market effects

Improves outlook for the medical imaging niche as margins expand.

Limited to U.S. micro‑cap investors.

Low; impact confined to HYPR shareholders.

Counterpoint

Target cut may be overly cautious given strong cash position and margin expansion.

Key entities

  • Hyperfine Inc.

    Medical imaging device maker (NASDAQ:HYPR).

  • B.Riley

    Equity research analyst who lowered the price target.

Related articles

$HYPRMed

What Hyperfine (HYPR) Said on Its Q3 Earnings Call

Hyperfine (HYPR) reported $13.8M revenue for the first nine months, up 66% YoY, with 36 systems sold. Management maintained its revenue forecast, citing capital equipment deal sizes and visibility. The company discussed its 'land-and-expand' strategy in health systems and progress in contrast imaging studies. Hyperfine also expanded internationally and explored new markets like memory clinics and wellness.

$HYPRMed

Hyperfine, Inc. Reports Third Quarter 2026 Financial Results

Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hyperfine, Inc. Reports Third Quarter 2026 Financial Results GUILFORD, Conn.--(BUSINESS WIRE)--November 9, 2026--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portab

$HYPRMedAI 9/10

Hyperfine expects Q3 revenue of $6M; shares jump 9%

Hyperfine HYPR reported preliminary Q3 2026 revenue of $6.0M, beating estimates and up 53% sequentially. Shares rose 9% premarket. Net cash burn improved 29% QoQ. Full-year revenue guidance remains $20M-$22M, with cash burn expected to decline 10% YoY. Results will be detailed on Nov 9, 2026.

$HYPRMed

Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to…

Hyperfine, Inc. (HYPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million Preliminary Revenue Represents 53% Sequential Quarterly Growth; Company Reaffirms 2026 Financial Gu

$HYPRMedAI 8/10

Hyperfine (HYPR) Q2 2026 Earnings Call Transcript

Hyperfine (HYPR) reported Q2 2026 revenue of $3.9 million, up 45% year over year, and first-half revenue of $7.8 million, up 62%. Gross margin was 50.7%. Net loss was $9.3 million. Cash was $43.5 million at June 30, 2026. Full-year 2026 guidance: revenue $20-$22 million, gross margin 50%-55%, cash burn $26-$28 million.